Stapokibart (CM310) in Atopic Dermatitis: A Narrative Review of a Next-Generation IL-4Rα Antagonist.
- 1Dermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China.
- 2The First School of Clinical Medicine, Southern Medical University, Guangzhou, China.
Abstract
Introduction
The interleukin (IL)-4/IL-13 signaling pathway is central to the pathogenesis of atopic dermatitis (AD). Stapokibart (CM310) is a novel humanized monoclonal antibody targeting the IL-4 receptor alpha (IL-4Rα) subunit.Objective
To summarize current evidence on the mechanism of action, clinical efficacy, safety, and therapeutic potential of stapokibart for moderate-to-severe AD.Methods
A narrative review was conducted based on a targeted search of PubMed/MEDLINE and ClinicalTrials.gov covering literature published from January 2015 to January 2026.Results
Stapokibart binds IL-4Rα with high affinity (KD = 0.25 nM), inhibiting downstream IL-4 and IL-13 signaling. In a phase 3 trial (N=500), stapokibart 300 mg every two weeks demonstrated significant improvements at Week 16, with 66.9% achieving EASI-75 (vs. 25.8% placebo) and 44.2% achieving IGA 0/1 (vs. 16.1% placebo; P<0.0001). Among responders, 92.5% maintained EASI-75 through Week 52. The treatment was generally well tolerated, with upper respiratory tract infections and injection-site reactions being the most common adverse events. Conjunctivitis occurred at low rates (5.0-5.9%).Conclusions
Stapokibart shows robust efficacy and a favorable safety profile in adults with moderate-to-severe AD, including sustained long-term responses and low conjunctivitis rates. While early data are encouraging, all comparisons with existing IL-4/IL-13 inhibitors are indirect, and further global phase 3 studies and real-world evidence are needed to define its role within treatment algorithms.
Related
- Targeted therapy in atopic dermatitis: Endotype heterogeneity, treatment sequencing, and lessons from a contracting pipeline: A narrative review
- Topical Calcium Thioglycolate for Severe Plantar Hyperkeratosis in Atopic Dermatitis: A Case Report
- Vitiligo developing during dupilumab treatment in a child with atopic dermatitis: a case report and literature review
- Subcorneal Pustular Dermatosis as a Complication of Upadacitinib Therapy in a Patient with Atopic Dermatitis: A Case Report
- Tryptophan Metabolism in Pediatric Atopic Dermatitis: Shared Mechanisms, Age-Specific Biomarkers, and Emerging Therapies
BibTeX
@article{ferreira2026stapokibart,
title = {{Stapokibart (CM310) in Atopic Dermatitis: A Narrative Review of a Next-Generation IL-4Rα Antagonist.}},
author = {Esmeraldito Ferreira and Tong Wu and Yongfeng Chen},
journal = {Dermatology practical \& conceptual},
year = {2026},
month = jul,
doi = {10.5826/dpc.1603a7230},
url = {https://europepmc.org/article/MED/42858405},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Stapokibart (CM310) in Atopic Dermatitis: A Narrative Review of a Next-Generation IL-4Rα Antagonist.
AU - Esmeraldito Ferreira
AU - Tong Wu
AU - Yongfeng Chen
PY - 2026
DA - 2026/07/31
JO - Dermatology practical & conceptual
DO - 10.5826/dpc.1603a7230
UR - https://europepmc.org/article/MED/42858405
AB - Introduction The interleukin (IL)-4/IL-13 signaling pathway is central to the pathogenesis of atopic dermatitis (AD). Stapokibart (CM310) is a novel humanized monoclonal antibody targeting the IL-4 receptor alpha (IL-4Rα) subunit.Objective To summarize current evidence on the mechanism of action, clinical efficacy, safety, and therapeutic potential of stapokibart for moderate-to-severe AD.Methods A narrative review was conducted based on a targeted search of PubMed/MEDLINE and ClinicalTrials.gov covering literature published from January 2015 to January 2026.Results Stapokibart binds IL-4Rα with high affinity (KD = 0.25 nM), inhibiting downstream IL-4 and IL-13 signaling. In a phase 3 trial (N=500), stapokibart 300 mg every two weeks demonstrated significant improvements at Week 16, with 66.9% achieving EASI-75 (vs. 25.8% placebo) and 44.2% achieving IGA 0/1 (vs. 16.1% placebo; P<0.0001). Among responders, 92.5% maintained EASI-75 through Week 52. The treatment was generally well tolerated, with upper respiratory tract infections and injection-site reactions being the most common adverse events. Conjunctivitis occurred at low rates (5.0-5.9%).Conclusions Stapokibart shows robust efficacy and a favorable safety profile in adults with moderate-to-severe AD, including sustained long-term responses and low conjunctivitis rates. While early data are encouraging, all comparisons with existing IL-4/IL-13 inhibitors are indirect, and further global phase 3 studies and real-world evidence are needed to define its role within treatment algorithms.
SN - 2160-9381
ER -